UK's SkinBioTherapeutics falls after delaying results amid investigation
** Shares of British skin-health company SkinBioTherapeutics SBTX.L down 32.3% at 6.5 pence ** Co announces delay of HY26 results until board investigation into former CEO is completed ** Co says shares expected to be suspended from April 1 until results are published ** Up to Thursday's close, stock had fallen 39.05% this year (Reporting by Simone Lobo in Bengaluru) ((Simone.Lobo@thomsonreuters.com, +919920570373))
Recent news on Skinbiotherapeutics
See all newsBrief: SkinBioTherapeutics Appoints Rachel Parsonage As CEO & Alyson Levett As Chair On Permanent Basis
SkinBioTherapeutics - Trading Statement
Brief: SkinBioTherapeutics Appoints Anita Slater To Start As Interim CFO
SkinBioTherapeutics - Appointment of Interim CFO
SkinBioTherapeutics - Holding(s) in Company